Sei Investments Co. Has $4.40 Million Position in Masimo Co. (NASDAQ:MASI)

Sei Investments Co. reduced its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,601 shares of the medical equipment provider's stock after selling 1,481 shares during the quarter. Sei Investments Co.'s holdings in Masimo were worth $4,397,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. State Street Corp grew its holdings in shares of Masimo by 0.7% during the 3rd quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock worth $191,837,000 after purchasing an additional 10,179 shares during the period. Geode Capital Management LLC increased its holdings in Masimo by 1.5% during the 3rd quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock worth $105,741,000 after purchasing an additional 11,984 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Masimo by 2.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider's stock valued at $62,456,000 after acquiring an additional 7,808 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its holdings in Masimo by 0.4% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 373,705 shares of the medical equipment provider's stock valued at $61,773,000 after buying an additional 1,522 shares during the last quarter. Finally, Corient Private Wealth LLC increased its holdings in shares of Masimo by 8,847.1% in the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider's stock valued at $57,472,000 after acquiring an additional 343,797 shares during the last quarter. 85.96% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Masimo Stock Performance

Shares of Masimo stock traded up $5.96 on Monday, reaching $150.36. The stock had a trading volume of 1,133,100 shares, compared to its average volume of 645,075. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The business's 50-day moving average price is $173.23 and its two-hundred day moving average price is $163.63. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The stock has a market cap of $8.12 billion, a P/E ratio of 103.70 and a beta of 1.28.

Masimo (NASDAQ:MASI - Get Free Report) last released its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.42 by $0.38. The firm had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. On average, sell-side analysts forecast that Masimo Co. will post 4.1 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. Wells Fargo & Company lifted their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research report on Wednesday, February 26th. Piper Sandler boosted their price target on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Raymond James boosted their target price on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a research note on Friday, December 27th. Finally, Needham & Company LLC restated a "hold" rating on shares of Masimo in a report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $194.80.

Insider Transactions at Masimo

In related news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Craig B. Reynolds sold 2,053 shares of the stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares of the company's stock, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 9.70% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.